MA34958B1 - Nouvelle forme cristalline vii d'agomelatine ,son procedes de preparation et utilisation et composition pharmaceutique la contenant - Google Patents

Nouvelle forme cristalline vii d'agomelatine ,son procedes de preparation et utilisation et composition pharmaceutique la contenant

Info

Publication number
MA34958B1
MA34958B1 MA36225A MA36225A MA34958B1 MA 34958 B1 MA34958 B1 MA 34958B1 MA 36225 A MA36225 A MA 36225A MA 36225 A MA36225 A MA 36225A MA 34958 B1 MA34958 B1 MA 34958B1
Authority
MA
Morocco
Prior art keywords
preparation
crystalline form
pharmaceutical composition
composition containing
form vii
Prior art date
Application number
MA36225A
Other languages
English (en)
Inventor
Yu Huang
Ling Tong
Xueyan Zhu
Hanbin Shan
Zhedong Yuan
Xiong Yu
Original Assignee
Shanghai Industitute Of Pharmaceutical Industry
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46855966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34958(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai Industitute Of Pharmaceutical Industry, Servier Lab filed Critical Shanghai Industitute Of Pharmaceutical Industry
Publication of MA34958B1 publication Critical patent/MA34958B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Glass Compositions (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

CETTE INVENTION CONCERNE UNE NOUVELLE FORME CRISTALLINE VII D'AGOMÉLATINE, SON PROCÉDÉ DE PRÉPARATION ET UTILISATION ET UNE COMPOSITION PHARMACEUTIQUE LA CONTENANT. LA NOUVELLE FORME CRISTALLINE A UNE BONNE PURETÉ, UNE FORME CRISTALLINE STABLE ET UNE BONNE REPRODUCTIBILITÉ ; SON PROCÉDÉ DE PRÉPARATION EST FACILE À AMPLIFIER ; ET ELLE EST SUPÉRIEURE À LA PLUPART DES FORMES CRISTALLINES PRÉCÉDEMMENT DÉCRITES EN TERMES DE STABILITÉ ET DE SOLUBILITÉ. PAR CONSÉQUENT, LA FORME CRISTALLINE VII SELON L'INVENTION PRÉSENTE UN AVANTAGE EN TERMES DE PRÉPARATION.
MA36225A 2011-03-23 2012-03-22 Nouvelle forme cristalline vii d'agomelatine ,son procedes de preparation et utilisation et composition pharmaceutique la contenant MA34958B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011100708280A CN102690210A (zh) 2011-03-23 2011-03-23 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
PCT/CN2012/072816 WO2012126385A1 (fr) 2011-03-23 2012-03-22 Nouvelle forme cristalline vii d'agomélatine, son procédé de préparation et utilisation et composition pharmaceutique la contenant

Publications (1)

Publication Number Publication Date
MA34958B1 true MA34958B1 (fr) 2014-03-01

Family

ID=46855966

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36225A MA34958B1 (fr) 2011-03-23 2012-03-22 Nouvelle forme cristalline vii d'agomelatine ,son procedes de preparation et utilisation et composition pharmaceutique la contenant

Country Status (31)

Country Link
US (1) US9527803B2 (fr)
EP (1) EP2690087B1 (fr)
JP (1) JP6203170B2 (fr)
KR (1) KR20130136544A (fr)
CN (2) CN102690210A (fr)
AR (1) AR085543A1 (fr)
AU (1) AU2012231547B2 (fr)
BR (1) BR112013024219A2 (fr)
CA (1) CA2829687C (fr)
CY (1) CY1119625T1 (fr)
DK (1) DK2690087T3 (fr)
EA (1) EA023297B1 (fr)
ES (1) ES2650604T3 (fr)
GE (1) GEP20156386B (fr)
HR (1) HRP20171831T1 (fr)
HU (1) HUE037264T2 (fr)
LT (1) LT2690087T (fr)
MA (1) MA34958B1 (fr)
MD (1) MD4391C1 (fr)
ME (1) ME02921B (fr)
MX (1) MX355552B (fr)
MY (1) MY185235A (fr)
NO (1) NO2690087T3 (fr)
PL (1) PL2690087T3 (fr)
PT (1) PT2690087T (fr)
RS (1) RS56444B1 (fr)
SG (1) SG193300A1 (fr)
SI (1) SI2690087T1 (fr)
UA (1) UA113058C2 (fr)
WO (1) WO2012126385A1 (fr)
ZA (1) ZA201306760B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
LT3027588T (lt) * 2013-07-29 2020-07-10 Les Laboratoires Servier Agomelatino ir sulfonrūgščių kompleksai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos
KR101470794B1 (ko) * 2014-06-30 2014-12-08 순천향대학교 산학협력단 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물
ES2959460T3 (es) 2015-03-31 2024-02-26 Fis Fabbrica Italiana Sintetici Spa Forma sólida de agomelatina
EP3466413A1 (fr) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Composition pharmaceutique contenant de l'agomelatine et son procédé de préparation
EP3466923A1 (fr) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Procédés de préparation d'agomélatine dans une forme cristalline

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US7498466B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
CN101781225A (zh) * 2009-11-21 2010-07-21 浙江华海药业股份有限公司 一种阿戈美拉汀晶形a制备方法
EP2319827A1 (fr) * 2009-11-09 2011-05-11 Ratiopharm GmbH Procédé pour la production d'une forme I polymorphe d'agomélatine
CN101704763B (zh) 2009-11-25 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀i型晶体的制备方法
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101792400B (zh) * 2010-03-16 2013-01-30 华东师范大学 一种阿戈美拉汀的合成方法
CN101921205B (zh) * 2010-08-30 2013-11-20 江苏恩华药业股份有限公司 阿戈美拉汀ⅰ晶型的制备方法
CN102452951B (zh) * 2010-10-25 2014-02-19 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物

Also Published As

Publication number Publication date
MY185235A (en) 2021-04-30
ME02921B (fr) 2018-10-20
ES2650604T3 (es) 2018-01-19
AU2012231547A1 (en) 2013-10-03
ZA201306760B (en) 2014-05-28
MD4391C1 (ro) 2016-08-31
EA201301066A1 (ru) 2014-02-28
SG193300A1 (en) 2013-10-30
AU2012231547A8 (en) 2013-10-24
CA2829687A1 (fr) 2012-09-27
SI2690087T1 (sl) 2017-12-29
RS56444B1 (sr) 2018-01-31
PT2690087T (pt) 2017-10-04
CN103476742B (zh) 2015-04-29
JP6203170B2 (ja) 2017-09-27
EP2690087B1 (fr) 2017-08-30
CA2829687C (fr) 2016-08-09
WO2012126385A1 (fr) 2012-09-27
HRP20171831T1 (hr) 2017-12-29
MD4391B1 (ro) 2016-01-31
CN102690210A (zh) 2012-09-26
NZ615707A (en) 2016-02-26
DK2690087T3 (en) 2017-12-04
UA113058C2 (xx) 2016-12-12
EA023297B1 (ru) 2016-05-31
US9527803B2 (en) 2016-12-27
MX355552B (es) 2018-04-23
EP2690087A4 (fr) 2014-09-17
HK1193087A1 (en) 2014-09-12
PL2690087T3 (pl) 2018-01-31
GEP20156386B (en) 2015-10-26
JP2014516341A (ja) 2014-07-10
MX2013010702A (es) 2013-10-01
EP2690087A1 (fr) 2014-01-29
BR112013024219A2 (pt) 2016-12-20
KR20130136544A (ko) 2013-12-12
HUE037264T2 (hu) 2018-08-28
US20140011883A1 (en) 2014-01-09
AR085543A1 (es) 2013-10-09
MD20130073A2 (en) 2014-03-31
CN103476742A (zh) 2013-12-25
AU2012231547B2 (en) 2015-11-19
NO2690087T3 (fr) 2018-01-27
CY1119625T1 (el) 2018-04-04
LT2690087T (lt) 2017-10-25

Similar Documents

Publication Publication Date Title
MA34958B1 (fr) Nouvelle forme cristalline vii d'agomelatine ,son procedes de preparation et utilisation et composition pharmaceutique la contenant
MA30724B1 (fr) Procede de preparation d'acide 4-amino-butyrique substitue par biaryle ou de derives de celui-ci et leur utilisation pour produire des inhibiteurs de nep.
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA29171B1 (fr) Formulation a compression directe et procede associe
MA31951B1 (fr) Nouveaux procedes
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
MA29627B1 (fr) Modifications cristallines de la pyraclostrobine
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
RU2014112319A (ru) Соединения и фармацевтические композиции для лечения вирусных инфекций
MA33063B1 (fr) Complexe d'hydrohalogenure d'agomelatine et procede de preparation de celui-ci
HUP0301117A2 (hu) Imidazolszármazék kináz inhibitorok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
HUP0300359A2 (hu) 2-Benzotiazolil-karbamid-származékok és protein kináz inhibitorként történő felhasználásuk és ezeket tartalmazó gyógyszerkészítmények
MA32087B1 (fr) Derives d'indole 2-carboxamides et d'azaindole 2-carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
UA105425C2 (ru) Кристаллическая форма агомелатина гидрохлорида гидрата и способ ее получения
UA83719C2 (ru) Кристаллическая форма iii агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
ES8703437A1 (es) Procedimiento para la preparacion de 4h-3,1-benzoxazin-4-- onas y compuestos relacionados
MA35158B1 (fr) Formulations topiques de type suspension comprenant un depsipeptide cyclique
MA34959B1 (fr) Agomelatine cristalline mixte (forme viii) ,son procede de preparation et utilisation et composistion pharmaceutique la contenant
MA33417B1 (fr) Compositions pharmaceutiques et formes solides
Yang et al. Synthesis and antiviral activities of novel gossypol derivatives
UY28737A1 (es) Compuestos farmacéuticamente activos
MA34054B1 (fr) Bromhydrate d'agomelatine hydrate et sa preparation
HUP0204154A2 (hu) Új benzotiadiazin vegyületek, eljárás előállításukra és ezen vegyületeket tartalmazó gyógyszerkészítmények